Impact of chelator treatment on post-transfusion hemochromatosis in thalassemic patients under Deferasirox
1 Faculty of Pharmacy -University of Algiers-1, Algeria.
2 Hussein Dey University Hospital Center, Algiers, Algeria.
Research Article
GSC Biological and Pharmaceutical Sciences, 2023, 22(03), 123–129.
Article DOI: 10.30574/gscbps.2023.22.3.0109
Publication history:
Received on 04 February 2023; revised on 11 March 2023; accepted on 14 March 2023
Abstract:
The management of beta thalassemia may require periodic blood transfusions, iron chelation therapy, and bone marrow or stem cell transplantation. This study is a descriptive retrospective analysis of clinical, biological, and therapeutic parameters to evaluate the impact and effectiveness of chelation therapy in managing post-transfusional hemochromatosis in 26 β-thalassemia patients treated at the Hussein Dey University Hospital Center in Algiers, Algeria. The results of this study show a certain correlation between the doses of iron chelators taken and the improvement in ferritin levels and creatinine clearance, which is indicative of a reduction in renal function impairment. Five profiles were identified based on this relationship. The study also found that all patients had normal kidney function, but there was a tendency towards a decrease in creatinine clearance, necessitating continuous monitoring. It is important to note that even with careful monitoring, complications of thalassemia may occur gradually and at a late onset. This study highlights the need to integrate pharmaceutical practices and introduce the concept of clinical pharmacy to improve adherence to long-term chelation therapy and ultimately enhance survival in children with major thalassemia.
Keywords:
β-thalassemia; Hemochromatosis; Iron chelation; Ferritin levels; Creatinine clearance
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
